GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » Cash Flow from Investing

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Cash Flow from Investing : $-0.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Hepion Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Hepion Pharmaceuticals gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Hepion Pharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for Hepion Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Cash Flow from Investing Chart

Hepion Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.09 -0.13 -0.01 -0.01

Hepion Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.02 - -

Hepion Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Hepion Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Hepion Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hepion Pharmaceuticals  (NAS:HEPA) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Hepion Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Hepion Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Hepion Pharmaceuticals's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Hepion Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Hepion Pharmaceuticals's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Hepion Pharmaceuticals spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Hepion Pharmaceuticals's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Hepion Pharmaceuticals gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Hepion Pharmaceuticals's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Hepion Pharmaceuticals spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Hepion Pharmaceuticals's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Hepion Pharmaceuticals gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Hepion Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Hepion Pharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Hepion Pharmaceuticals's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Hepion Pharmaceuticals paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Hepion Pharmaceuticals's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Hepion Pharmaceuticals paid $0.00 Mil for other investing activities.


Hepion Pharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Executives
Peter Wijngaard director 8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster officer: Chief Scientific Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan officer: Chief Financial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: CEO and President
Donald E Garlikov 10 percent owner 41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson director
Thomas Phd Adams director
Gabriel Cerrone 10 percent owner VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai officer: Chief Medical Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein director, officer: Chief Executive Officer 1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa director C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung officer: Chief Financial Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Headlines

From GuruFocus